Partial agonists and full antagonists at the human and murine bradykinin B-1 receptors

被引:27
|
作者
MacNeil, T
Feighner, S
Hreniuk, DL
Hess, JF
VanderPloeg, LHT
机构
关键词
bradykinin B-1 receptor; antagonist; functional assay;
D O I
10.1139/cjpp-75-6-735
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We developed a functional assay to evaluate the activity of kinin peptides at the human and mouse bradykinin (BK) B-1 receptors. The photoprotein aequorin expressed in 293-AEQ17 cells was used to measure calcium mobilization due to activation of the human or mouse B-1 receptors by kinin peptides. The B-1 agonists des-Arg(9)-BK and des-Arg(10)-kallidin activated the human receptor (EC50 = 112 and 5 nM, respectively), whereas the B-1 peptide antagonists des-Arg(9),Leu(8)-BK and des-Arg(10),Leu(9)-kallidin showed no activation. At the murine receptor, the agonists des-Arg(9)-BK and des-Arg(10)-kallidin activated the receptor with EC50 values of 39 and 23 nM, respectively. In contrast, the two peptide antagonists showed significant agonism at the murine receptor. Thirty-nine and 44% agonism of the mouse receptor was observed with des-Arg(9),Leu(8)-BK (EC50 = 56 nM) and des-Arg(10),Leu(9)-kallidin (EC50 = 177 nM). Two recently described kinin analogues, [Lys-Lys(0),Hyp(3),Igl(5),D-Igl(7),Oic(8),des-Arg(9)]BK and [D-Arg(0),Hyp(3),Igl(5)D-Igl(7),Oic(8),des-Arg(9)]BK (B9858 and des-Arg(9)-B9430), failed to agonize the mouse receptor. These peptides were potent antagonists of des-Arg(10)-kallidin- and des-Arg(9)-BK-induced bioluminescence at the cloned human and mouse B-1 receptors.
引用
收藏
页码:735 / 740
页数:6
相关论文
共 50 条
  • [31] HYPERALGESIA AND FEVER IN RATS FOLLOWING ICV ADMINISTERED LIPOPOLYSACCHARIDE - EFFECTS OF BRADYKININ B-1 AND B-2 RECEPTOR ANTAGONISTS
    WALKER, K
    DRAY, A
    PERKINS, MN
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 : P95 - P95
  • [32] Non-peptide antagonists and agonists of the bradykinin B2 receptor
    Heitsch, H
    CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) : 913 - 928
  • [33] KININ B-1 RECEPTORS - A REVIEW
    MARCEAU, F
    IMMUNOPHARMACOLOGY, 1995, 30 (01): : 1 - 26
  • [34] Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model
    Sevcik, MA
    Ghilardi, JR
    Halvorson, KG
    Lindsay, TH
    Kubota, K
    Mantyh, PW
    JOURNAL OF PAIN, 2005, 6 (11): : 771 - 775
  • [36] Spontaneous human B2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists - Effect of basal desensitization
    Fathy, DB
    Leeb, T
    Mathis, SA
    Leeb-Lundberg, LMF
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (42) : 29603 - 29606
  • [37] EFFECTS OF PEPTIDE AND NONPEPTIDE ANTAGONISTS OF BRADYKININ B-2 RECEPTORS ON THE VENOCONSTRICTOR ACTION OF BRADYKININ
    MARCEAU, F
    LEVESQUE, L
    DRAPEAU, G
    RIOUX, F
    SALVINO, JM
    WOLFE, HR
    SEOANE, PR
    SAWUTZ, DG
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 269 (03): : 1136 - 1143
  • [38] Functional characterization of bradykinin analogues on recombinant human bradykinin B1 and B2 receptors
    Simpson, PB
    Woollacott, AJ
    Hill, RG
    Seabrook, GR
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 392 (1-2) : 1 - 9
  • [39] In vivo pharmacological profile of novel, potent, stable BK antagonists at B-1 and B-2 receptors
    Hanson, WL
    McCullough, RG
    Selig, WM
    Wieczorek, M
    Ross, S
    Whalley, ET
    Stewart, JM
    Gera, L
    IMMUNOPHARMACOLOGY, 1996, 33 (1-3): : 191 - 193
  • [40] CLONING AND PHARMACOLOGICAL CHARACTERIZATION OF A RABBIT BRADYKININ B-1 RECEPTOR
    MACNEIL, T
    BIERILO, KK
    MENKE, JG
    HESS, JF
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1995, 1264 (02): : 223 - 228